[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Incheon St.Mary's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100608209","ai-assisted-chemotherapy-side-effect-management-100608209",false,"NCT07198581","AI-Assisted Chemotherapy Side Effect Management","A Randomized Controlled Trial of AI-Assisted Chemotherapy Side Effect Management in Solid Tumor Patients","ALLIANCE","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old) diagnosed with histologically confirmed solid malignancies (breast cancer, colorectal cancer)\n* Patients scheduled to receive at least 3 months of systemic chemotherapy\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Severe psychiatric disorders\n* Cognitive impairment affecting ability to report symptoms\n* Presence of cancer-related symptoms prior to chemotherapy initiation\n* Concurrent participation in trials evaluating other symptom management interventions Inability to provide informed consent Life expectancy less than 6 months","ALL","18 Years",{"count":20,"type":21},174,"ESTIMATED","INTERVENTIONAL",[24],"NA","This two-stage adaptive randomized controlled trial evaluates the feasibility and preliminary efficacy of large language model (LLM)-assisted intervention for managing chemotherapy side effects in patients with solid tumors. Adults with histologically confirmed breast or colorectal cancer scheduled for at least 3 months of systemic chemotherapy will be randomly assigned (1:1) to receive either LLM-assisted care or standard care.\n\nThe study employs an adaptive design with initial enrollment of 60 patients (30 per arm), followed by interim analysis. Unless enrollment is stopped for safety reasons identified at interim analysis, an additional 114 patients will be enrolled for a maximum total of 174 patients (87 per arm).\n\nIn the intervention group, healthcare providers input anonymized patient symptom data into an LLM system using sessions where data is not retained, which generates evidence-based management recommendations. Physicians critically review these recommendations and use them as reference for clinical decision-making, with final treatment decisions remaining under physician discretion. The control group receives standard supportive care without LLM assistance.\n\nThe primary outcome is change in health-related quality of life measured by EORTC QLQ-C30 global health status\u002FQoL scale from baseline to end of treatment. Secondary outcomes include proportion achieving clinically meaningful improvement (≥8-point increase), treatment adherence, dose intensity, healthcare resource utilization, and physician acceptance of LLM recommendations.",[27,28],"Breast Cancer","Colorectal Cancer",[30,31,32,33,34,35],"Large Language Model","LLM","Breast cancer","Side effect","Supportive care","colorectal cancer","RECRUITING","2026-04-17",{"date":39,"type":40},"2026-04-22","ACTUAL",{"date":42,"type":40},"2025-11-12",{"date":44,"type":21},"2026-10-31",{"name":46,"class":47},"Incheon St.Mary's Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100613609","phase-4-heartburn-gastroesophageal-reflux-disease-100613609","NCT07268820","Heartburn, Gastroesophageal Reflux Disease","A Multicenter, Double-blind, Randomized, Investigator-initiated Trial to Evaluate the Degree of Symptom Relief of Zastaprazan and Esomeprazole in Patients With Erosive Reflux Disease With Night-time Heartburn Symptoms","GERD","Inclusion Criteria:\n\n1. Korean adults aged 19 years or older as of the date of written consent\n2. Those diagnosed with erosive gastroesophageal reflux disease based on upper gastrointestinal endoscopy (EGD)\n3. Those who reported nighttime heartburn for more than 3 months at the time of screening (Visit 1)\n4. Those who voluntarily decided to participate and provide written informed consent\n\nExclusion Criteria:\n\n1. Those who cannot undergo upper gastrointestinal endoscopy (EGD)\n2. Individuals with a history of drug or alcohol abuse (within the past year)\n3. Individuals who have received other investigational products within one month prior to the screening visit (Visit 1)\n4. In addition to the above, individuals with clinically significant findings that the investigator deems medically inappropriate for the present study","19 Years",{"count":59,"type":21},160,[61],"PHASE4","Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation.\n\nGERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life.\n\nThis study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).",[55],"2025-12-16",{"date":66,"type":40},"2025-12-23",{"date":68,"type":40},"2025-07-07",{"date":70,"type":21},"2026-09-30",{"name":46,"class":47},10,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":48},"100554937","preoperative-vs-pathologic-size-in-breast-cancer-a-prospective-study-100554937","NCT06505577","Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study","Concordance Between Preoperative Assessments and Pathologic Size Measurements in Breast Cancer: a Prospective Observational Study","Inclusion Criteria:\n\nAdult patients (≥ 19 years old) diagnosed with breast cancer (invasive and in situ).\n\nPatients scheduled for surgical resection of the tumor Availability of both preoperative tumor size assessments and pathologic measurements post-surgery\n\nExclusion Criteria:\n\nPatients with recurrent breast cancer Inflammatory breast cancer Patients who did not undergo surgery Patients whose preoperative tumor size data is not available or deficient for analyzing",{"count":81,"type":21},600,"1 Year","OBSERVATIONAL","Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging. Inadequate resection margins necessitate reoperation, leading to increased psychological stress, costs, and potentially compromised cosmetic outcomes and prognosis.\n\nAccurate preoperative assessment of resection extent is crucial and involves various factors, including imaging studies, physical examinations, tumor molecular subtypes, and intraductal carcinoma components. This prospective observational study aims to identify and integrate multiple predictive factors to enhance surgical planning and minimize reoperation rates in breast cancer patients.",[86,87],"Mastectomy","Breast Neoplasm Malignant Primary",[32,86,89],"Ductal carcinoma in situ","2025-04-03",{"date":92,"type":40},"2025-04-06",{"date":94,"type":40},"2024-08-01",{"date":96,"type":21},"2027-08-30",{"name":46,"class":47},""]